Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
Condition: Anal Cancer
MeSH terms: Anus Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to
      the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in
      chemotherapy, such as fluorouracil and mitomycin C, work in different ways to stop the growth
      of tumor cells, either by killing the cells or by stopping them from dividing. Giving
      radiation therapy together with 5-fluorouracil (5-FU) and mitomycin C may kill more tumor
      cells.

      PURPOSE: This phase II trial is studying the side effects and how well giving
      intensity-modulated radiation therapy together with fluorouracil and mitomycin C works in
      treating patients with invasive anal cancer.
    

Detailed description: 
      OBJECTIVES:

      Primary

        -  Determine if dose-painted, intensity-modulated radiation therapy (IMRT), fluorouracil,
           and mitomycin C decreases the combined rate of gastrointestinal and genitourinary
           adverse events (grade II or greater) by at least 15% in the first 90 days after the
           start of treatment in patients with primary invasive carcinoma of the anal canal
           compared to patients treated on the radiotherapy, fluorouracil, and mitomycin C arm on
           clinical trial RTOG 98-11.

      Secondary

        -  Determine the feasibility of performing IMRT in these patients in a cooperative group
           setting.

        -  Evaluate adverse events experienced by patients treated with this regimen and to
           decrease the grade 2 and higher and grade 3 and higher overall adverse event rates by
           15% or 20% as compared to the radiotherapy and mitomycin C arm of RTOG 98-11.

        -  Evaluate the total duration of radiotherapy.

        -  Evaluate the efficacy of this regimen, in terms of locoregional failure, disease-free
           survival, time to colostomy, colostomy-free survival, and overall survival of these
           patients.

        -  Determine clinical complete response at 8 weeks after completion of study treatment.

      OUTLINE: This is a multicenter study.

      Patients receive mitomycin C IV over 10-30 minutes on days 1 and 29 and fluorouracil IV
      continuously over 96 hours on days 1-4 and 29-32. Patients also undergo dose-painted
      intensity-modulated radiation therapy once daily, 5 days a week, for 5½ to 6 weeks beginning
      on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed every 3 months for 1 year, every 6
      months for 1 year, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 59 patients will be accrued for this study.
    

Intervention name(s): fluorouracil; mitomycin C; Intensity-modulated radiation therapy
Intervention type(s): Drug; Drug; Radiation
Intervention description(s): 1000 mg/m^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.; 10 mg/m^2 intravenous therapy on day 1 and day 29 of radiation therapy.; Prescription dose depends on tumor staging.
T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.
T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.
For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes > 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx.
Intervention MeSH terms: Fluorouracil; Mitomycins; Mitomycin
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: stage II anal cancer; stage IIIA anal cancer; stage IIIB anal cancer; basaloid carcinoma of the anus; cloacogenic carcinoma of the anus; squamous cell carcinoma of the anus